5
PROTEIN SYNTHESIS INHIBITORS Work by targeting bacterial ribosome Mammalian (eukaryotic) cells have 80S ribosomes composed of 60S and 40S subunits Bacteria (prokaryotic) cells have 70S ribosomes composed or 50S and 30S subunits  AMINO- GLYCOSIDES TETRA-CYCLINES CHLORAM- PHENICOL MACROLIDES LINCOSAMIDES Streptomycin Gentamicin Tobramycin Amikacin Netilmicin Neomycin Kanamycin Tetracycline Doxycycline Minocycline Demeclocycline Oxytetracycline Chloram- phenicol Erythromycin Clarithromycin Azithromycin Clindamycin Lincomycin AMINOGLYCOSIDES Bactericidal  Inhibit protein synthesis All bind irreversibly to the 30S ribosomal subunit and interfere with protein synthesis in susceptible bacteria Used to treat infections caused by several aerobic gram-negative bacteria Given parenterally Mechanisms of Resistance:  o Plasmid-mediated synthesis of aminoglycoside –inactivating enzymes such as acetyltransferase, nucleotidyltransferase and phosphotransfe rase which modify and inactivate these drugs o Changes in the 30S ribosomal subunit resulting in decreased affinity between the drug and 30S subunit o Decreased membrane permeability

Antimicrobials 3

Embed Size (px)

Citation preview

8/13/2019 Antimicrobials 3

http://slidepdf.com/reader/full/antimicrobials-3 1/5

PROTEIN SYNTHESIS INHIBITORS 

Work by targeting bacterial ribosome

Mammalian (eukaryotic) cells have 80S ribosomes composed of 60S and

40S subunits 

Bacteria (prokaryotic) cells have 70S ribosomes composed or 50S and 30Ssubunits 

AMINO-

GLYCOSIDES 

TETRA-CYCLINES  CHLORAM-

PHENICOL

MACROLIDES  LINCOSAMIDES 

Streptomycin

Gentamicin

Tobramycin

Amikacin

Netilmicin

Neomycin

Kanamycin

Tetracycline

Doxycycline

Minocycline

Demeclocycline

Oxytetracycline

Chloram-

phenicol

Erythromycin

Clarithromycin

Azithromycin

Clindamycin

Lincomycin

AMINOGLYCOSIDES 

Bactericidal 

Inhibit protein synthesis

All bind irreversibly to the 30S ribosomal subunit and interfere with protein

synthesis in susceptible bacteria 

Used to treat infections caused by several aerobic gram-negative bacteriaGiven parenterally 

Mechanisms of Resistance: 

o  Plasmid-mediated synthesis of aminoglycoside –inactivating

enzymes such as acetyltransferase, nucleotidyltransferase and

phosphotransferase which modify and inactivate these drugs 

o  Changes in the 30S ribosomal subunit resulting in decreased affinity

between the drug and 30S subunit 

o  Decreased membrane permeability

8/13/2019 Antimicrobials 3

http://slidepdf.com/reader/full/antimicrobials-3 2/5

 

TETRACYCLINES 

Large group of related agents 

Effective against both aerobic and anaerobic gr (+) and (-) bacteria,

rickettsiae, mycoplasma and chlamydiae 

Can cross placenta but have poor CNS penetration 

8/13/2019 Antimicrobials 3

http://slidepdf.com/reader/full/antimicrobials-3 3/5

 

Mechanisms of Resistance: 

o  Resistance usually results from acquisition of an R-factor which may

code for the following: 

  Active efflux mechanism that pumps drug out of themicroorganism

  Loss of cytoplasmic transport proteins which are required for

entry into susceptible organisms 

  Changes in membrane permeability to the drug

8/13/2019 Antimicrobials 3

http://slidepdf.com/reader/full/antimicrobials-3 4/5

 

CHLORAMPHENICOL 

Broad spectrum antibiotic 

Inhibits protein synthesis in bacteria by binding to the 50S ribosomal

subunit 

Remains an important drug for life-threatening infections such as

meningitis, typhoid fever 

Mechanism for Resistance 

o  Resistance to gram (-) bacteria to this drug is usually caused by

a plasmid acquired by conjugation which may code for the ff: 

o  R-factors coding for Acetyl-CoA transferase which inactivates

chloramphenicol

o  Decreased ability to penetrate the organism

Side effects: 

o  Anemia 

o  Gray baby syndrome

o  Nausea, vomiting, diarrhes and perineal irritation

8/13/2019 Antimicrobials 3

http://slidepdf.com/reader/full/antimicrobials-3 5/5

 

MACROLIDES 

Characterized by a macrocyclic lactone ring to which sugars are attached

Erythromycin – drug prototype

Mechanisms of Resistance: o  Plasmids coding for specific enzymes (erythromycin esterases)

which inactivate these drugs

o  Methylation of an adenine residue on the 23S rRNA binding site

leads to decreased affinity for the 50S ribosomal subunit

o  Defective uptake of the drug by the microbe

CLINICAL USES: 

• Spectrum: anaerobic gram (+) cocci and bacilli

• Pneumonia

• Legionnaires’ disease 

• Pertusis

• Diphtheria

SIDE EFFECT: 

• GI side effects: nausea, vomiting, diarrhea 

• Cholestatic hepatitis